Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METIMMOX-2
2022-500027-76-00Phase 2Authorised
- Sponsor
- Akershus University Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Akershus University Hospital. Primary endpoint: Progression-free survival. Planned start May 2022; status: authorised.
02
Drugs
nivolumaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-500027-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500027-76-00.